Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Ermisch, Michael, Bucsics, Anna, Vella Bonanno, Patricia, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Fürst, Jurij, Garuolienė, Kristina, van der Graaff, Martin, Gulbinovič, Jolanta, Haycox, Alan, Jones, Jan, Joppi, Roberta, Laius, Ott, Langner, Irene, Martin, Antony P., Markovic-Pekovic, Vanda, McCullagh, Laura, Magnusson, Einar, Nilsen, Ellen, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Sauermann, Robert, Schuurman, Ad, Ramos, Ricardo, Vlahovic-Palcevski, Vera, Zara, Corinne, Godman, Brian
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2016
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://ncbi.nlm.nih.gov/pubmed/27733828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00305
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados